Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Bronchiolitis Acute
Interventions: Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Months to 24 Months
Enrollment: 2,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 60
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Genital Herpes
Interventions: AG-707; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Indianapolis, Indiana • Portland, Oregon • Seattle, Washington

Conditions: Low Back Pain
Interventions: Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 20 Years to 70 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 15 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 8 more

Conditions: Mental Health Issue, PTSD, Pain, Chronic Pain, Chronic Disease
Interventions: Not listed
Lead sponsor: Advanced Integrative Medical Science Institute; Other
Eligibility: Not listed
Enrollment: 500 participants
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson Disease
Interventions: ExAblate Pallidotomy, Sham ExAblate Pallidotomy; Device
Lead sponsor: InSightec; Industry
Eligibility: 30 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 11
States / cities: Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Alcoholism
Interventions: Prazosin medication, Placebo medication; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 51
States / cities: Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more

Conditions: Bone Cancer
Interventions: OST31-164; Drug
Lead sponsor: Emerald Clinical Inc.; Industry
Eligibility: 12 Years to 39 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • San Diego, California + 18 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: obinutuzumab (RO5072759), rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure; Procedure · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 133
States / cities: Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Depression, Bipolar
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 33 more

Conditions: Depression
Interventions: Behavioral Activation Therapy, Treatment as Usual- Psychotherapy; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 11 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Solid Tumors
Interventions: IMC-A12; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 3
States / cities: Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington

Conditions: Breast Cancer
Interventions: Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 1,341,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Davis, California • San Francisco, California • Chicago, Illinois + 4 more

Conditions: Ulcerative Colitis
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 25
States / cities: Dothan, Alabama • Los Angeles, California • Bristol, Connecticut + 21 more

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI); Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 60 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 11 more

Conditions: Hepatitis
Interventions: Larsucosterol, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 98
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more

Conditions: Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: valproic acid; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 15
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol; Drug
Lead sponsor: UCB Celltech; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 21 more

Conditions: Diarrhea, HIV Infections
Interventions: Crofelemer; Drug
Lead sponsor: Shaman Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Search by objective public record fields.

I-DECIDE After Bronchiolitis Hospitalization

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

AIMS Medical Outcomes Study

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Study of the Medication Prazosin for Alcohol Dependence

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

Osteosarcoma Maintenance Therapy With OST31-164

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Behavioral Activation With Depressed Adolescents

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients